Enanta Pharma (ENTA) Tops Q3 EPS by 4c. Revs Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2017
August 7, 2017 4:01 PM EDTWebcast and Conference Call today at 4:30 p.m. ET
Cash and marketable securities totaled $235.3 million at June 30, 2017 Royalty revenue for the quarter was $7.5 million Milestone payments totaling $65 million earned following AbbVies EU approval of MAVIRET (glecaprevir/pibrentasvir) in July, and U.S. approval of MAVYRET (glecaprevir/pibrentasvir) in August RSV and NASH/PBC clinical programs continue to advance toward new stages next quarterWATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta... More
